N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Rachel A. Freedman,Rebecca Gelman,Jeffrey S. Wefel,Michelle E. Melisko,Kenneth R. Hess,Roisin M. Connolly,Catherine Van Poznak,Polly A. Niravath,Shannon Puhalla,Nuhad K. Ibrahim,Kimberly L. Blackwell,Beverly Moy,Christina I. Herold,Minetta C. Liu,Alarice C. Lowe,Nathalie Y. R. Agar,N. Ryabin,Sarah Farooq,Elizabeth V. Lawler,Mothaffar F. Rimawi,Ian E. Krop,Antonio C. Wolff,Eric P. Winer,Nan Lin +23 more
TL;DR: Although neratinib had low activity and did not meet the threshold for success, 12.5% of patients received six or more cycles, and patients in the study experienced a decreased quality of life over time.
Journal ArticleDOI
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer
Seth A. Wander,Ofir Cohen,Ofir Cohen,Xueqian Gong,Gabriela N. Johnson,Gabriela N. Johnson,Jorge E. Buendia-Buendia,Jorge E. Buendia-Buendia,Maxwell R. Lloyd,Dewey Kim,Dewey Kim,Flora Luo,Pingping Mao,Karla Helvie,Kailey J. Kowalski,Kailey J. Kowalski,Utthara Nayar,Adrienne G. Waks,Stephen Parsons,Ricardo Martinez,Lacey M. Litchfield,Xiang S. Ye,Chunping Yu,Valerie M. Jansen,John R. Stille,Patricia S Smith,Gerard J. Oakley,Quincy Chu,Gerald Batist,Melissa E. Hughes,Jill D. Kremer,Levi A. Garraway,Eric P. Winer,Sara M. Tolaney,Nan Lin,Sean Buchanan,Nikhil Wagle +36 more
TL;DR: Whole exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, which may define therapeutic opportunities in patients.
Journal ArticleDOI
Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib
Patrick G. Morris,Carol L. Chen,Richard M. Steingart,Martin Fleisher,Nan Lin,Beverly Moy,Steven E. Come,Steven Sugarman,A. Abbruzzi,Robert Lehman,Sujata Patil,Maura N. Dickler,Heather L. McArthur,Eric P. Winer,Larry Norton,Clifford A. Hudis,Chau T. Dang +16 more
TL;DR: In patients receiving ddAC→PTL, cTnIs are commonly detected and these elevations may precede changes in LVEF but, as assessed in this trial, do not predict CHF.
Journal ArticleDOI
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
Paul W. Sperduto,Norbert Kased,David Roberge,Samuel T. Chao,Ryan Shanley,Xianghua Luo,Penny K. Sneed,Penny K. Sneed,John H. Suh,Robert J. Weil,Ashley W. Jensen,Paul D. Brown,Helen A. Shih,John P. Kirkpatrick,Laurie E. Gaspar,John B. Fiveash,Veronica Chiang,Jonathan P.S. Knisely,Christina Maria Sperduto,Nan Lin,Minesh P. Mehta +20 more
TL;DR: The relationship of breast cancer subtype to the time interval from primary diagnosis to development of BM, number of BM at initial BM presentation and survival is investigated to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.